Curis is a biotechnology company based in Lexington, Town of, MA, dedicated to developing innovative therapeutics for the treatment of cancer. With a focus on hematologic malignancies and other cancers, Curis is committed to improving the lives of cancer patients through the development and commercialization of differentiated therapies.
Through collaborations with partners and scientific research collaborations, Curis is advancing its pipeline of therapeutics, including Emavusertib CA-4948, Fimepinostat, CA-170, CA-327, and Erivedge. With a strong emphasis on clinical studies and proof of principle, Curis aims to bring effective treatments to market and make a positive impact in the fight against cancer.
Generated from the website